# EyePoint Shares DURAVYU Trial Results

> EyePoint reveals DURAVYU's Phase III results for wet age-related macular degeneration.
- Title: EyePoint Shares DURAVYU Trial Results · Seekingalpha
- Summary: EyePoint reveals DURAVYU's Phase III results for wet age-related macular degeneration. EyePoint Inc. reported DURAVYU's Phase III top-line results for wet…
- Keywords: eyepoint, duravyu, lucia, phase iii, wet age-related macular degeneration, nasdaq:eypt, money, business, Shares, Trial, Results, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4956112-eyepoint-inc-eypt-discusses-lucia-phase-iii-topline-results-for-duravyu-in-wet-age-related
- Author: SA Transcripts
- Published: 2026-10-21T23:06:17+00:00
- Read time: 1 min
- Topics: eyepoint, duravyu, lucia, phase iii, wet age-related macular degeneration, nasdaq:eypt, money, business
## EyePoint Inc. (EYPT)
EyePoint Inc. published a slide deck discussing DURAVYU's Phase III top-line results for wet age-related macular degeneration.
## DURAVYU Trial Results
DURAVYU's Phase III top-line results for wet age-related macular degeneration were discussed by EyePoint Inc. in a slide deck.
## Slide Deck Published
EyePoint Inc. released a slide deck for this event with 162.54K followers on SA Transcripts.
## Key takeaway

EyePoint Inc. reported DURAVYU's Phase III top-line results for wet age-related macular degeneration.